Company news
X4 Pharmaceuticals, Inc. news in 2019
X4 Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)
December 29, 2019
X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
November 25, 2019
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome
November 11, 2019
X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights
November 6, 2019
X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia
November 4, 2019
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel
November 3, 2019
X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients
September 29, 2019
X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
September 22, 2019
X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development
September 17, 2019
Decks in 2019
- Technical Presentation (September 2019)
Technical · 15 slides · Sep 30, 2019
- Investor Presentation (April 2019)
Investor deck · 20 slides · Apr 1, 2019